Salaric, I;
Sabalic, M;
Alajbeg, I;
(2017)
Opiorphin in burning mouth syndrome patients: a case-control study.
Clinical Oral Investigations
, 21
(7)
pp. 2363-2370.
10.1007/s00784-016-2031-9.
Preview |
Text
Sabalic Opiorphin_Salaric_et_al_2017_author_manuscript.pdf - Accepted Version Download (495kB) | Preview |
Abstract
Objectives Opiorphin is a pentapeptide isolated from human saliva that suppresses pain from chemically induced inflammation and acute physical pain. Burning mouth syndrome (BMS) is a chronic condition of a burning sensation in the mouth, where no underlying dental or medical cause can be identified. We aimed to measure the level of opiorphin in whole unstimulated (UWS) and stimulated (SWS) saliva of patients with BMS. Materials and methods Originally developed and validated LC-MS/MS method was used for opiorphin quantification. Samples were obtained from 29 BMS patients and 29 age- and sex-matched controls. Results The average concentration of opiorphin in UWS and SWS in the BMS group was 8.13 ± 6.45 and 5.82 ± 3.59 ng/ml, respectively. Opiorphin in BMS patients’ UWS was significantly higher, compared to the control group (t = 2.5898; p = 0.0122). SWS opiorphin levels were higher, but not significantly, in BMS patients than in controls. Conclusions Our results indicate that higher quantities of salivary opiorphin in BMS may be a consequence of chronic pain, but we cannot exclude that they occur as a result of emotional and behavioral imbalances possibly associated with BMS. To our knowledge, this is the first original article measuring opiorphin in a pain disorder. Clinical relevance Opiorphin may be a measurable biomarker for chronic pain, which could help in objectifying otherwise exclusively a subjective experience. Increased opiorphin could serve as a universal objective indicator of painful conditions. Since opiorphin may also reflect emotional and socio-relational imbalances occurring with BMS, it could as well represent a biomarker for BMS. Knowledge on opiorphin’s involvement in pain pathways could contribute to developing new clinical diagnostic methods for BMS.
| Type: | Article |
|---|---|
| Title: | Opiorphin in burning mouth syndrome patients: a case-control study |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1007/s00784-016-2031-9 |
| Publisher version: | https://doi.org/10.1007/s00784-016-2031-9 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Dentistry, Oral Surgery & Medicine, Opiorphin, Burning mouth syndrome, Saliva, Chromatography, Liquid, Spectrometry, Mass, ORAL SENSORY COMPLAINTS, UNDERLYING MECHANISMS, SALIVARY-GLANDS, TOLERANCE, PATHWAYS, MOTILITY, GENE, RATS, MICE |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Eastman Dental Institute |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10073295 |
Archive Staff Only
 |
View Item |
